Lilly's Lasmiditan NDA Review Could Hinge On US FDA's Migraine Guidance
Potential first-in-class on-demand oral migraine treatment would complement new prevention products from Lilly, Amgen and Teva.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Lilly noted strong growth for new products, but gains seen in the fourth quarter included older products with limited potential going forward. That puts even more pressure on the R&D pipeline and the company's revised guidance, but executives were optimistic about future growth drivers.
Lilly laid out its 2019 financial forecast and commercial and R&D goals during an investor event in New York. While there were no big surprises, the company updated investors on important catalysts in diabetes, immunology, oncology and pain.